Company profile for Cyrano Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. The funds will be used to complete a Phase 2 clinical trial of the company’s lead product, CYR-064, in the U.S. and Europe. As part of the financ...
Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. The funds will be used to complete a Phase 2 clinical trial of the company’s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company’s board of directors. Currently no FDA-approved therapy for this serious condition afflicting over 15 million.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
MacArthur Blvd. NW, #20 Washington, DC 20016
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/cyrano-therapeutics-completes-enrollment-in-phase-2-flavor-trial-of-cyr-064-for-post-viral-smell-loss-302425007.html

PR NEWSWIRE
10 Apr 2025

https://www.prnewswire.com/news-releases/kyorin-and-cyrano-therapeutics-enter-into-an-option-agreement-for-cyr-064-for-the-treatment-of-post-viral-loss-of-smell-in-japan-302378067.html

PR NEWSWIRE
18 Feb 2025

https://www.prnewswire.com/news-releases/cyrano-therapeutics-announces-the-launch-of-an-investigator-initiated-clinical-study-evaluating-cyr-064-for-the-loss-of-smell-hyposmia-in-parkinsons-disease-patients-302367016.html

PR NEWSWIRE
04 Feb 2025

https://www.prnewswire.com/news-releases/cyrano-therapeutics-secures-9-0-million-series-b-financing-to-advance-clinical-development-of-cyr-064-for-treatment-of-post-viral-smell-loss-302031744.html

PR NEWSWIRE
16 Jan 2024

https://www.prnewswire.com/news-releases/cyrano-therapeutics-enrolls-first-patient-in-phase-2-trial-of-cyr-064-for-post-viral-smell-loss-hyposmia-301954527.html

PR NEWSWIRE
12 Oct 2023

https://www.clinicaltrialsarena.com/news/cyrano-trial-nasal-spray-therapy-hyposmia/

CLINICAL TRIALS ARENA
19 Jan 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty